Drug intelligence / Profile preview

psil-mir200c + pmis mir200a

Development stage: Unknown
Modality: RNA Therapeutics → Nucleic Acid Therapeutics

Overview

This combination involves two microRNAs, psil-mir200c and pmis mir200a, which are part of the miR-200 family. MicroRNAs are small RNA molecules that regulate gene expression by binding to messenger RNA (mRNA), thereby influencing various biological processes. The miR-200 family is known for its role in cancer, particularly in regulating epithelial-to-mesenchymal transition (EMT) and affecting tumor progression and drug resistance[3][4][5]. The specific mechanisms of psil-mir200c and pmis mir200a in this context are not detailed in the available literature.

Beyond the preview

Go deeper on psil-mir200c + pmis mir200a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on psil-mir200c + pmis mir200a.

Explore the full profile